Current Environment: Production

Jonathan Paolino | Medical Services

Programs & Services

Jonathan Paolino | Education

Undergraduate School

College of the Holy Cross

Worcester, MA

Medical School

University of Massachusetts at Worcester

Worcester, MA

Internship

Pediatrics

Massachusetts General Hospital

Boston, MA

Residency

Pediatrics

Massachusetts General Hospital

Boston, MA

Fellowship

Pediatric Oncology

Dana-Farber Cancer Institute/Boston Children's Hospital

Boston, MA

Jonathan Paolino | Publications

  1. Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Blood Cancer J. 2024 10 31; 14(1):191. View Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Abstract

  2. Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative. Pediatr Qual Saf. 2024 Sep-Oct; 9(5):e771. View Outpatient Management of Fever and Neutropenia in Low-risk Children with Solid Tumors: A Quality Improvement Initiative. Abstract

  3. Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress. Dev Cell. 2024 08 19; 59(16):2203-2221.e15. View Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress. Abstract

  4. IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia. Biomedicines. 2024 Jan 01; 12(1). View IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia. Abstract

  5. Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Clin Cancer Res. 2023 11 14; 29(22):4613-4626. View Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Abstract

  6. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Blood Adv. 2023 04 11; 7(7):1092-1102. View Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Abstract

  7. Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure. Front Oncol. 2022; 12:1016318. View Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure. Abstract

  8. Simulated Umbilical Venous Catheter Placement Improves Resident Competence and Confidence. Cureus. 2020 Oct 05; 12(10):e10810. View Simulated Umbilical Venous Catheter Placement Improves Resident Competence and Confidence. Abstract

  9. Peripheral blood smears of children with multisystem inflammatory syndrome demonstrate prominence of early myeloid forms with morphologic evidence of toxic change. Pediatr Blood Cancer. 2021 01; 68(1):e28551. View Peripheral blood smears of children with multisystem inflammatory syndrome demonstrate prominence of early myeloid forms with morphologic evidence of toxic change. Abstract

  10. Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia. Pediatr Blood Cancer. 2019 07; 66(7):e27679. View Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia. Abstract

  11. The Massachusetts General Hospital Guide to Medical Care in Patients with Autism Spectrum Disorder. 2018.

  12. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015 Jan; 64(1):77-83. View Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Abstract

  13. Usefulness of pancreatitis-associated protein, a novel biomarker, to predict severity of disease in ambulatory patients with heart failure. Am J Cardiol. 2014 Jan 01; 113(1):123-6. View Usefulness of pancreatitis-associated protein, a novel biomarker, to predict severity of disease in ambulatory patients with heart failure. Abstract

  14. J Crohns Colitis. A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab. 2013; 7(1):S248.

  15. Inflammatory Bowel Diseases. No association between vedolizumab exposure and serum JC virus levels. 2011; 17(Suppl 1):S56.

BESbswy